S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.49 (-0.27%)
AAPL   139.38 (+1.83%)
MSFT   226.47 (+0.67%)
FB   275.01 (+0.78%)
GOOGL   1,892.50 (+0.44%)
AMZN   3,293.00 (-0.42%)
TSLA   845.61 (+0.07%)
NVDA   548.20 (-1.17%)
BABA   258.34 (-0.64%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.62 (+1.19%)
NIO   61.82 (+5.97%)
T   28.96 (+0.45%)
F   11.52 (-0.09%)
ACB   10.56 (-5.46%)
BA   206.11 (-0.63%)
DIS   172.75 (+0.86%)
NFLX   564.96 (-2.57%)
GILD   66.97 (-0.01%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.49 (-0.27%)
AAPL   139.38 (+1.83%)
MSFT   226.47 (+0.67%)
FB   275.01 (+0.78%)
GOOGL   1,892.50 (+0.44%)
AMZN   3,293.00 (-0.42%)
TSLA   845.61 (+0.07%)
NVDA   548.20 (-1.17%)
BABA   258.34 (-0.64%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.62 (+1.19%)
NIO   61.82 (+5.97%)
T   28.96 (+0.45%)
F   11.52 (-0.09%)
ACB   10.56 (-5.46%)
BA   206.11 (-0.63%)
DIS   172.75 (+0.86%)
NFLX   564.96 (-2.57%)
GILD   66.97 (-0.01%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.49 (-0.27%)
AAPL   139.38 (+1.83%)
MSFT   226.47 (+0.67%)
FB   275.01 (+0.78%)
GOOGL   1,892.50 (+0.44%)
AMZN   3,293.00 (-0.42%)
TSLA   845.61 (+0.07%)
NVDA   548.20 (-1.17%)
BABA   258.34 (-0.64%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.62 (+1.19%)
NIO   61.82 (+5.97%)
T   28.96 (+0.45%)
F   11.52 (-0.09%)
ACB   10.56 (-5.46%)
BA   206.11 (-0.63%)
DIS   172.75 (+0.86%)
NFLX   564.96 (-2.57%)
GILD   66.97 (-0.01%)
S&P 500   3,841.47 (-0.30%)
DOW   30,996.98 (-0.57%)
QQQ   325.49 (-0.27%)
AAPL   139.38 (+1.83%)
MSFT   226.47 (+0.67%)
FB   275.01 (+0.78%)
GOOGL   1,892.50 (+0.44%)
AMZN   3,293.00 (-0.42%)
TSLA   845.61 (+0.07%)
NVDA   548.20 (-1.17%)
BABA   258.34 (-0.64%)
CGC   33.80 (+0.72%)
GE   11.15 (+0.72%)
MU   82.18 (-3.33%)
AMD   92.62 (+1.19%)
NIO   61.82 (+5.97%)
T   28.96 (+0.45%)
F   11.52 (-0.09%)
ACB   10.56 (-5.46%)
BA   206.11 (-0.63%)
DIS   172.75 (+0.86%)
NFLX   564.96 (-2.57%)
GILD   66.97 (-0.01%)
Log in
NASDAQ:NARI

Inari Medical Stock Forecast, Price & News

$107.07
+1.53 (+1.45 %)
(As of 01/22/2021 04:30 PM ET)
Add
Compare
Today's Range
$103.14
Now: $107.07
$108.11
50-Day Range
$64.69
MA: $79.69
$103.05
52-Week Range
$39.55
Now: $107.07
$108.11
Volume450,115 shs
Average Volume677,908 shs
Market Capitalization$5.22 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.
Inari Medical logo

MarketRank

Overall MarketRank

0.80 out of 5 stars

Medical Sector

1113th out of 1,921 stocks

Surgical & Medical Instruments Industry

105th out of 168 stocks

Analyst Opinion: 1.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NARI
CUSIPN/A
CIKN/A
Phone877-923-4747
Employees199

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$5.22 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableNot Optionable
$107.07
+1.53 (+1.45 %)
(As of 01/22/2021 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NARI News and Ratings via Email

Sign-up to receive the latest news and ratings for NARI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Inari Medical (NASDAQ:NARI) Frequently Asked Questions

Is Inari Medical a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Inari Medical stock.
View analyst ratings for Inari Medical
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Inari Medical?

Wall Street analysts have given Inari Medical a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Inari Medical wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Inari Medical's CEO?

1,448 employees have rated Inari Medical CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Inari Medical's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Inari Medical's next earnings date?

Inari Medical is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Inari Medical
.

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) issued its earnings results on Thursday, November, 12th. The company reported $0.12 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.04) by $0.16. The business earned $38.70 million during the quarter, compared to the consensus estimate of $26.53 million. Inari Medical's revenue for the quarter was up 172.5% on a year-over-year basis.
View Inari Medical's earnings history
.

What guidance has Inari Medical issued on next quarter's earnings?

Inari Medical updated its fourth quarter 2020 Pre-Market earnings guidance on Wednesday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $47.9-48.9 million, compared to the consensus revenue estimate of $38.5 million.

What price target have analysts set for NARI?

6 analysts have issued 1-year price targets for Inari Medical's stock. Their forecasts range from $56.00 to $112.00. On average, they anticipate Inari Medical's share price to reach $87.67 in the next year. This suggests that the stock has a possible downside of 18.1%.
View analysts' price targets for Inari Medical
or view Wall Street analyst' top-rated stocks.

Who are some of Inari Medical's key competitors?

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Honeywell International (HON), The Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), The Procter & Gamble (PG) and Bristol-Myers Squibb (BMY).

Who are Inari Medical's key executives?

Inari Medical's management team includes the following people:
  • Mr. William H. Hoffman, CEO, Pres & Director (Age 53, Pay $800k)
  • Mr. Mitchell C. Hill, Chief Financial Officer (Age 61, Pay $393.28k)
  • Mr. Andrew J. Hykes, Chief Operating Officer (Age 47, Pay $572.56k)
  • Ms. Angela Ahmad, Gen. Counsel
  • Mr. Eric Khairy, VP Marketing
  • Mr. John R. Borrell, VP of Sales (Age 53)
  • Dr. Thomas M. Tu M.D., Chief Medical Officer (Age 47)

When did Inari Medical IPO?

(NARI) raised $110 million in an initial public offering (IPO) on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

What is Inari Medical's stock symbol?

Inari Medical trades on the NASDAQ under the ticker symbol "NARI."

Who are Inari Medical's major shareholders?

Inari Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Hershey Trust Co. (0.05%), Hamilton Lane Advisors LLC (0.02%), First Hawaiian Bank (0.01%) and Regents of The University of California (0.01%). Company insiders that own Inari Medical stock include Andrew Hykes, Cynthia L Lucchese, Donald B Milder, Gilde Healthcare Cooperatieve, Mitch C Hill, Presidio Management Group X Ll, Thomas Tu and William Hoffman.
View institutional ownership trends for Inari Medical
.

Which institutional investors are buying Inari Medical stock?

NARI stock was bought by a variety of institutional investors in the last quarter, including Hershey Trust Co., Hamilton Lane Advisors LLC, First Hawaiian Bank, and Regents of The University of California. Company insiders that have bought Inari Medical stock in the last two years include Andrew Hykes, Cynthia L Lucchese, Mitch C Hill, Presidio Management Group X Ll, and William Hoffman.
View insider buying and selling activity for Inari Medical
or or view top insider-buying stocks.

How do I buy shares of Inari Medical?

Shares of NARI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Inari Medical's stock price today?

One share of NARI stock can currently be purchased for approximately $107.07.

How big of a company is Inari Medical?

Inari Medical has a market capitalization of $5.22 billion. Inari Medical employs 199 workers across the globe.

What is Inari Medical's official website?

The official website for Inari Medical is www.inarimedical.com.

How can I contact Inari Medical?

Inari Medical's mailing address is 9 Parker Suite 100, Irvine CA, 92618. The company can be reached via phone at 877-923-4747 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.